<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dianthus Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc</link>
<description>Latest news and press releases for Dianthus Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 12 Mar 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dianthus-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355ed178dffbe2df0ed55b.webp</url>
<title>Dianthus Therapeutics Inc.</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc</link>
</image>
<item>
<title>Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-closing-of-its-upsized-dollar719-million-underwritten-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-closing-of-its-upsized-dollar719-million-underwritten-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares</guid>
<pubDate>Thu, 12 Mar 2026 20:01:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it closed its previously announced underwritten public offering of 8,470,989 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional</description>
</item>
<item>
<title>Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-pricing-of-upsized-dollar625-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-pricing-of-upsized-dollar625-million-underwritten-public-offering</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-recent-business-achievements-including-go-decision-for-phase-3-captivate-cidp-trial-and-reports-q4-and-fy-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-recent-business-achievements-including-go-decision-for-phase-3-captivate-cidp-trial-and-reports-q4-and-fy-2025-financial-results</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants</description>
</item>
<item>
<title>Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-announces-early-go-decision-following-interim-responder-analysis-in-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneuropathy-cidp</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-announces-early-go-decision-following-interim-responder-analysis-in-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneuropathy-cidp</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing</description>
</item>
<item>
<title>Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-proposed-dollar400-million-underwritten-public-offering-25</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-proposed-dollar400-million-underwritten-public-offering-25</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneuropathy-cidp</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneuropathy-cidp</guid>
<pubDate>Sun, 08 Mar 2026 05:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated</description>
</item>
<item>
<title>Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to</description>
</item>
<item>
<title>Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-guggenheim-emerging-outlook-biotech-summit-2026</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-guggenheim-emerging-outlook-biotech-summit-2026</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to</description>
</item>
<item>
<title>Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to</description>
</item>
<item>
<title>Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/leads-biolabs-and-dianthus-therapeutics-announce-initiation-phase-1-trial-lbl-047</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/leads-biolabs-and-dianthus-therapeutics-announce-initiation-phase-1-trial-lbl-047</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while</description>
</item>
<item>
<title>Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-8th-annual-evercore-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-8th-annual-evercore-healthcare-conference-2025-11</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to</description>
</item>
<item>
<title>Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24 Phase 2</description>
</item>
<item>
<title>Dianthus Therapeutics to Participate in Four Investor Conferences During November</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-four-investor-conferences-during-november-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-participate-four-investor-conferences-during-november-2025-11</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to</description>
</item>
<item>
<title>Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-new-claseprubart-data-presented-during-2025-aanem</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-new-claseprubart-data-presented-during-2025-aanem</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting</description>
</item>
<item>
<title>Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-announces-exclusive-license-agreement-leads-biolabs-dnth212</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-announces-exclusive-license-agreement-leads-biolabs-dnth212</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously</description>
</item>
<item>
<title>Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-claseprubart-data-presentations-planned-2025-aanem</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-highlights-claseprubart-data-presentations-planned-2025-aanem</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to</description>
</item>
<item>
<title>Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-closing-its-upsized-288-million-underwritten</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-closing-its-upsized-288-million-underwritten</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated</description>
</item>
<item>
<title>Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-pricing-upsized-251-million-underwritten-public</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-pricing-upsized-251-million-underwritten-public</guid>
<pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated</description>
</item>
<item>
<title>Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-proposed-150-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-inc-announces-proposed-150-million-underwritten-public-offering</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated</description>
</item>
<item>
<title>Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile</title>
<link>https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-announces-positive-data-claseprubart-dnth103-phase-2-magic</link>
<guid isPermaLink="true">https://6ix.com/company/dianthus-therapeutics-inc/news/dianthus-therapeutics-announces-positive-data-claseprubart-dnth103-phase-2-magic</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily</description>
</item>
</channel>
</rss>